Osgep Inhibitors
Chemical inhibitors of Osgep function through various molecular pathways to attenuate the activity of this protein. Cyclosporin A operates by inhibiting calcineurin, a phosphatase that can activate transcription factors involved in the upregulation of Osgep. When calcineurin is inhibited, these transcription factors remain in a phosphorylated, and therefore inactive, state, which results in a decrease in Osgep levels. Rapamycin, another inhibitor, targets the mTOR pathway by binding to FKBP12, and the resultant complex impedes mTOR's role in promoting protein synthesis, including the synthesis of Osgep. This leads to a reduced capacity of cells to produce Osgep. Similarly, Wortmannin and LY294002 inhibit PI3K, an enzyme that acts upstream of mTOR, leading to the downregulation of pathways that enhance Osgep synthesis. The inhibition by these compounds results in diminished functional Osgep activity.
Further regulating Osgep, Triciribine specifically targets and inhibits Akt, a kinase that is a crucial intermediary in the PI3K/Akt/mTOR pathway, which is known to regulate protein synthesis. By inhibiting Akt, Triciribine curtails the pathway's output, thereby reducing Osgep synthesis. U0126 and PD98059 are compounds that inhibit MEK, which is part of the ERK pathway. The ERK pathway is another route through which protein synthesis can be modulated. By inhibiting this pathway, these chemicals indirectly decrease the activity of Osgep. Additionally, SB203580 and SP600125 inhibit p38 MAP kinase and JNK, respectively, both of which are involved in stress response signaling that can affect Osgep regulation. Inhibition of these kinases by SB203580 and SP600125 reduces the functional activity of Osgep. Leflunomide inhibits dihydroorotate dehydrogenase, an enzyme critical for pyrimidine synthesis, which is necessary for the synthesis of all proteins, including Osgep. Bortezomib, on the other hand, blocks the proteasome's function, leading to the accumulation of proteins and triggering a cellular stress response that can result in the downregulation of the protein synthesis machinery, indirectly affecting Osgep production. Lastly, Thapsigargin, by inhibiting SERCA, disrupts calcium homeostasis and induces endoplasmic reticulum stress, which can also contribute to a decrease in Osgep synthesis.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Inhibits calcineurin, which when active, can dephosphorylate various transcription factors that may lead to upregulation of Osgep. By inhibiting calcineurin, Cyclosporin A indirectly inhibits the dephosphorylation, thus maintaining transcription factors in an inactive state, leading to a decrease in Osgep function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Binds to FKBP12 and the complex inhibits mTOR, a kinase that can positively influence protein synthesis including proteins like Osgep. Inhibition of mTOR leads to reduced protein synthesis capacity, thus functionally inhibiting Osgep. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Inhibits PI3K, which is upstream of the Akt/mTOR pathway, a pathway that can enhance protein synthesis including that of Osgep. Inhibition of PI3K by Wortmannin leads to downregulation of this pathway, thus inhibiting the function of Osgep. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, similarly to Wortmannin, leading to a decreased activity of the Akt/mTOR pathway, which is implicated in the synthesis of proteins such as Osgep. The inhibition of this pathway by LY294002 results in a functional inhibition of Osgep. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Specifically inhibits Akt, which is downstream of PI3K and upstream of mTOR, leading to a reduction in protein synthesis including proteins like Osgep. By inhibiting Akt, Triciribine functionally inhibits the pathways responsible for Osgep activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Inhibits MEK, which is upstream of the ERK pathway, a pathway that can indirectly upregulate protein synthesis including Osgep. By inhibiting MEK, U0126 indirectly leads to a functional inhibition of the ERK pathway and thus Osgep. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Functions as a MEK inhibitor, similar to U0126, leading to decreased activation of the ERK pathway, which may be involved in the regulation of protein synthesis, including Osgep. The inhibition of ERK pathway by PD98059 results in functional inhibition of Osgep. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAP kinase which is involved in stress responses that can include upregulation of proteins such as Osgep. Inhibition of p38 MAP kinase by SB203580 can lead to functional inhibition of Osgep. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, which can regulate transcription factors that control the synthesis of proteins like Osgep. By inhibiting JNK, SP600125 functionally inhibits pathways that could lead to the upregulation of Osgep. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
Inhibits dihydroorotate dehydrogenase which is essential for pyrimidine synthesis, necessary for DNA replication and the synthesis of proteins including Osgep. Leflunomide therefore can functionally inhibit the synthesis of Osgep. | ||||||